2,5-二氟-4-碘吡啶 | 1017793-20-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,5-二氟-4-碘吡啶
• 英文名称: 2,5-difluoro-4-iodopyridine
• CAS: 1017793-20-2
• 化学式: C₅H₂F₂IN
• 分子量: 240.979
• InChiKey: OBVRKNZQNKGNTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  209.7±35.0 °C(Predicted)
• 密度：
  2.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光，并保存在惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,5-Difluoro-4-iodopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,5-Difluoro-4-iodopyridine
CAS number: 1017793-20-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H2F2IN
Molecular weight: 241.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二氟-4-碘吡啶 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 N-甲基吗啉 、 盐酸 、 potassium phosphate 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 、 水 、 caesium carbonate 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 6.0h， 生成 (2R)-4-[4-(4-Chloro-2-fluorophenyl)-5-fluoro-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide
  参考文献：
  名称：

  FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

  摘要：

  本发明涉及一种新型羟羧酸衍生物的类别，其作为LpxC抑制剂的用途，更具体地说，其用于治疗细菌感染。

  公开号：

  US20120232083A1
• 作为产物：
  描述：

  2,5-二氟吡啶 在 正丁基锂 、 二异丙胺 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.5h， 以79%的产率得到2,5-二氟-4-碘吡啶
  参考文献：
  名称：

  （R）-α-杂芳基丙酸的不对称合成的可伸缩，伸缩式氢解-酶促脱羧工艺

  摘要：

  对映体纯的α-芳基丙酸是药物研究的有用组成部分，可以使用来自相应丙二酸的芳基丙二酸脱羧酶（AMDases）通过酶途径获得。然而，丙二酸的固有不稳定性是该方法的主要缺点，在该方法中，可能发生自发脱羧，随后侵蚀对映选择性并产生外消旋产物。对于我们希望使用该方法获得的一组N-杂环丙酸，这一点尤其明显。在本文中，我们描述了一种克服自发脱羧问题的方法，在该过程中，相应的二苄基丙二酸酯在双相甲苯-碱性水性缓冲液混合物中进行氢解，并伸缩进入随后的AMDase步骤。

  DOI：

  10.1021/acs.oprd.0c00397

文献信息

• CDK激酶抑制剂
  申请人：山东轩竹医药科技有限公司

  公开号：CN104910137B

  公开（公告）日：2017-04-19

  本发明属于医药技术领域，具体涉及通式(Ⅰ)所示的CDK激酶抑制剂、其药学上可接受的盐、其酯、其溶剂化物以及他们的立体异构体，其中R1、R2、R3、R4、R5、n如说明书中所定义。本发明还涉及这些化合物的制备方法，含有这些化合物的药物制剂和药物组合物，以及该化合物、其药学上可接受的盐、其酯、其溶剂化物以及他们的立体异构体在制备治疗和/或预防由CDK激酶介导的癌症相关疾病的药物中的应用。
• Chemical Compounds
  申请人：AstraZeneca AB

  公开号：US20160376287A1

  公开（公告）日：2016-12-29

  Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

  提供了一系列新颖的吡啶或嘧啶衍生物，可以抑制CDK9，并可能对治疗过度增殖性疾病有用。特别是这些化合物在治疗增殖性疾病方面具有用途，如癌症，包括血液恶性肿瘤，如急性髓细胞白血病，多发性骨髓瘤，慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤，Burkitt淋巴瘤，滤泡性淋巴瘤以及实体肿瘤，如乳腺癌，肺癌，神经母细胞瘤和结肠癌。
• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• [EN] NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2<br/>[FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE DE TYPE 2
  申请人：UNIV VANDERBILT

  公开号：WO2016149324A1

  公开（公告）日：2016-09-22

  Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.

  描述了代谢型谷氨酸受体2（mGlu2）的负变构调节剂，包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗受试者的抑郁症、焦虑症、强迫症、认知障碍、阿尔茨海默病或自闭症谱系障碍的方法。
• [EN] N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE À LIAISON N, UTILES COMME AGENTS ANTIBACTÉRIENS
  申请人：PFIZER

  公开号：WO2011073845A1

  公开（公告）日：2011-06-23

  The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).

  本发明涉及一类新的羟肟酸衍生物，它们作为LpxC抑制剂的用途，更具体地用于治疗细菌感染。公式（I）。